Re Re -evaluation and Safe -evaluation and Safe ty/Efficacy for the Kamp ty/Efficacy for the Kamp o Medicine In Japan o Medicine In Japan 日日日日日日日日日 日日日日日日日 日日日 ・ Prof. Motoyoshi Satake Prof. Motoyoshi Satake Ochanomizu University Ochanomizu University
23
Embed
Re -evaluation and Safety/Efficacy for the Kampo Medicine In Japan Re -evaluation and Safety/Efficacy for the Kampo Medicine In Japan 日本の再評価制度と...
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
ReRe -evaluation and Safety/Effic-evaluation and Safety/Efficacy for the Kampo Medicine In Jacy for the Kampo Medicine In J
apanapan日本の再評価制度と
漢方薬の安全性・有効性
Prof. Motoyoshi Satake Prof. Motoyoshi Satake
Ochanomizu UniversityOchanomizu University
PMS Systems
PMS System : consists of three main systems
Reevaluation
SpontaneousADR Reporting
Reexamination
Early Post-Marketing Phase Vigilance (6 mths)EPPV
Post-marketing surveillance (PMS) System in Japan
The Ministry of Health , Labor and Welfare
PMDA
MHLW
Pharmaceuticals and Medical Devices Agency
Periodic Safety Update Reports
19711971~~
19801980~~ 19971997
~~
20012001~~19671967
~~
Post-marketing surveillance ( PMS ) systems in
Japan
NDANew
Drug
Approval
Adverse Drug Reaction and Infectious Disease Reporting System
Reexamination system Reevaluation
system
Periodic Safety Reports
6years in Principle (4 ~ 10years)
EPPV
Initial 2 years : every 6 months
Thereafter : every year PMDA
MHLW
6months after launch
report
report
every 5 years
report
Launch of new products Early Post-Marketing Phase Vigilance
Pharmaceuticals and Medical Devices Agency
The Ministry of Health , Labor and Welfare
consists of three main systems
Post-marketing Surveillance
ReexaminationNew Drug Approval
ReevaluationDrug QualityReevaluation
4-6-10 years (5 years) (5 years)
Ad hoc reevaluation
Reevaluation
ADR Reporting System
R&D Phase
Re-evaluation test by double blind test for the ethical Kampo medicines
These ethical Kampo medicines finished the re-evaluation test in 200These ethical Kampo medicines finished the re-evaluation test in 2004. 4.
Ministry will be reported the re-evaluation near future. Ministry will be reported the re-evaluation near future.
Double blind test used the Syosaikoto 小柴胡湯 for the common cold
1.Patient category The patient been taken ill before 5 days who being t
he cough and bad feeling inside the mouth or the cough with appetite
2.Test medicines (1) the ethical Syosaikoto extract granule ( TJ-
9 ) (2) placebo granule3.Method for the test (1)Test style : double blind test (2)Period for the administration : test period is on
e week. When the patient has been recover, the medical doctor stops to administration.
4.Main evaluation point (1)Effecacy(1)Effecacy :: Total improvement Score
(2)Safety(2)Safety :: Grade of the safetyGrade of the safety (3)Usefulness(3)Usefulness :: Grade of the usefulnessGrade of the usefulness
Double blind test used the SyosaikotoDouble blind test used the Syosaikoto 小柴胡湯小柴胡湯 eextract xtract granule for the common cold for the common cold
【 【 Main evaluation pointMain evaluation point 】】
Total Improvement Score
Group distinctimpro-vement
mode-rate
nochange
worsemore thanimprovem
ent
under themoderateimprovem
ent
total Certification
Syosaikoto 18 66 31 14 2 84 47 131 p=0.001
13.7% 50.4% 23.7% 10.7% 1.5% 64.1% 35.9% Wilcoxon
Placebo 9 43 42 23 2 52 67 119 p=0.001
7.6% 36.1% 35.3% 19.3% 1.7% 43.7% 56.3% Fisher
Double blind test used Double blind test used the Syosaikotothe Syosaikoto 小柴胡湯小柴胡湯 extract extract granule for the for the comcom
mon coldmon cold(( improvement Score in different symptom groupimprovement Score in different symptom group ))
improvement Score in different symptom group
Item Group distinctimpro-vementmode-rate
no change worse
morethan
improvement
underthe
moderate
total Certification
TJ-9 31 35 8 20 3 66 31 97 p=0.021
32.0% 36.1% 8.2% 20.6% 3.1% 68.0% 32.0% Wilcoxon
pracebo 10 33 8 19 4 43 31 74 p=0.201
13.5% 44.6% 10.8% 25.7% 5.4% 58.1% 41.9% Fisher
TJ-9 9 44 6 9 3 53 18 71 p=0.047
12.7% 62.0% 8.5% 12.7% 4.2% 74.6% 25.4% Wilcoxon
pracebo 3 39 6 15 4 42 25 67 p=0.145
4.5% 58.2% 9.0% 22.4% 6.0% 62.7% 37.3% Fisher
TJ-9 12 22 2 5 0 34 7 41 p=0.035
29.3% 53.7% 4.9% 12.2% 0.0% 82.9% 17.1% Wilcoxon
pracebo 4 19 3 7 1 23 11 34 p=0.175
Cough out phlegm
appetile
Jointpain・musclepain
Double blind test used the Double blind test used the OrengedokutoOrengedokuto 黄連解毒湯黄連解毒湯 ff
or complication inor complication in hypertensionhypertension1.Patient category1.Patient category The complication in hypertension is The complication in hypertension is (1)exitement (irritate) (1)exitement (irritate)
(2)mild spirit (3)sleep difficulty (4) rush of blood the head (2)mild spirit (3)sleep difficulty (4) rush of blood the head (5)flush. Test patient is one of them. (5)flush. Test patient is one of them.
2.Test medicines2.Test medicines (1) the ethical Orengedokuto extract granule(TJ-15), 6 capsules per day (2) placebo granule3.Method for the test3.Method for the test (1)Test style : double blind test(1)Test style : double blind test (2) Period for the administration :test period is four wee(2) Period for the administration :test period is four wee
k. Total weeks for administration is eight weeks.k. Total weeks for administration is eight weeks.4.Main evaluation point4.Main evaluation point (1) Efficacy(1) Efficacy :: Total improvement Score (2) Safety(2) Safety :: Grade of the safetyGrade of the safety (3) Usefulness(3) Usefulness :: Grade of the usefulnessGrade of the usefulness
Item clasification TJ-15 PlaceboCertification
(Wilcoxon)minimum -2 -2
center 1 0
maximam 3 3
average 0.7 0.5
minimum -1 -2
center 1 0
maximam 3 2
average 0.7 0.4
minimum -1 -2
center 0 0
maximam 3 2
average 0.6 0.5
minimum -1 -1
center 0 0
maximam 2 2
average 0.4 0.3
minimum -1 -2
center 0 0
maximam 2 3
average 0.7 0.5
sleep dificulty
p=0.035
p=0.022
p=0.523
p=0.437
p=0.354
rush of blood to the head
flush
elecitement (irritate)
mild sprit
Double blind test used the Double blind test used the OrengedokutoOrengedokuto 黄連解毒湯黄連解毒湯 for for complicacomplication in hypertensiontion in hypertension
Safety for the ethical Kampo MediciSafety for the ethical Kampo Medicinesnes
①① A manufacturer will collect similar reports from A manufacturer will collect similar reports from
now on.now on.
②② Revision of relevant information in the precautionsRevision of relevant information in the precautions
of the package insert.of the package insert.
③ ③ Distribution of a notice revised precautions. Distribution of a notice revised precautions.
④ ④ Recall of defective products .Recall of defective products .
⑤⑤ Suspension of manufacture and selling and productSuspension of manufacture and selling and product
recall. recall.
⑥ ⑥ Apply for partial change approval, such as changes of Apply for partial change approval, such as changes of
indications, dosage and administration.indications, dosage and administration.
Actions to ensure safety (manufacturers)
The mention of ADR which does the origin in the crude drugs , on the package insert
①①Patients with aldosteronismPatients with aldosteronism
② ② Patients with myopathyPatients with myopathy
③③Patients with hypokalemiaPatients with hypokalemia
[ – : These diseases or symptoms may be ag① ③[ – : These diseases or symptoms may be ag① ③gravated.]gravated.]
①②③①②③
When a licorice is When a licorice is contained as a contained as a quantity for 1 day quantity for 1 day more than 2.5g.more than 2.5g.
Important Important PrecautionsPrecautions
①①Since this product contains Glycyrrhiza, careful Since this product contains Glycyrrhiza, careful attention should be paid to the serum potassium lattention should be paid to the serum potassium level, blood pressure, etc., and if any abnormality ievel, blood pressure, etc., and if any abnormality is observed, administration should be discontinues observed, administration should be discontinued. d.
②②When this product is coadministered with other When this product is coadministered with other Kampo-preparationsKampo-preparations(Japanese traditional herbal medi(Japanese traditional herbal medi
cines)cines), etc., attention should be paid to the duplica, etc., attention should be paid to the duplication of the contained crude drugs. tion of the contained crude drugs.
Mention it in all of Mention it in all of the licorice the licorice containing containing prescriptions.prescriptions.
Glycyrrhizae Radix 〔 1 〕Notification
NotificationLiterature
The ADR which does the origin in the crude drugs 2The ADR which does the origin in the crude drugs 2
ItemItem DescriptionDescription CaseCase
Drug InteraDrug Intera
ctionsctions (1)(2)(3)(4)(1)(2)(3)(4)
When a licorice When a licorice is contained as is contained as a quantity for 1 a quantity for 1 day day more than more than 2.5g.2.5g.
(1)(2)(1)(2)
When a licorice When a licorice is contained as is contained as a quantity for 1 a quantity for 1 day day under under 2.5g.2.5g.
Glycyrrhizae Radix 〔 2 〕
DrugsDrugs Signs, Symptoms, Signs, Symptoms, and Treatmentand Treatment
Mechanism Mechanism and Risk and Risk FactorsFactors
(4)Thiazide diuretic(4)Thiazide diuretics s TrichlormethiazideTrichlormethiazide
Pseudoaldosteronism Pseudoaldosteronism is likely to occur. Beis likely to occur. Besides, myopathy is liksides, myopathy is likely to occur as aely to occur as a rresultesult of hypokalemof hypokalemia.ia.
(Refer to the section (Refer to the section “Clinically significant “Clinically significant adverse reactions”.)adverse reactions”.)
Since glycyrrhizinSince glycyrrhizinic acid and diuretiic acid and diuretics have an accelcs have an accelerating action on erating action on the potassium exthe potassium excretion at the rencretion at the renal tubules, an accal tubules, an acceleration of decreeleration of decrease in the serum ase in the serum potassium level hpotassium level has been suggestas been suggested.ed.
Notification
The ADR which does the origin in the crude drugs 3The ADR which does the origin in the crude drugs 3The Case of shakuyakukanzoto contains Glycyrrhizae Radix
(1)Pseudoaldosteronism(1)Pseudoaldosteronism: : Pseudoaldosteronism suchPseudoaldosteronism such as hypokalemia, increased blood pressure, retentias hypokalemia, increased blood pressure, retenti
on of sodium/body fluid, on of sodium/body fluid, edema,edema, increased body weight, etc. may occurincreased body weight, etc. may occur. The patie. The patient should be carefully monitored (measurement of serum potassium level, etc.), annt should be carefully monitored (measurement of serum potassium level, etc.), and if any abnormality is observed, administration should be discontinued and appropd if any abnormality is observed, administration should be discontinued and appropriate measures such as administration of potassium preparations should be taken.riate measures such as administration of potassium preparations should be taken.
The possibility that congestive heart failure, ventricular fibrillation, ventricular tacThe possibility that congestive heart failure, ventricular fibrillation, ventricular tachycardia (including Torsades de Pointes) may occur cannot be ruled out,hycardia (including Torsades de Pointes) may occur cannot be ruled out, and the p and the patient should be carefully monitored (measurement of serum potassium levels, etatient should be carefully monitored (measurement of serum potassium levels, etc.). Ifc.). If any abnormal findings such as palpitations, breathlessness, malaise, dizzine any abnormal findings such as palpitations, breathlessness, malaise, dizziness, syncope, etc. are observed, administration of the drug should be discontinued ass, syncope, etc. are observed, administration of the drug should be discontinued and appropriate therapeutic measures taken.nd appropriate therapeutic measures taken.
(3)Myopathy(3)Myopathy : :
As a result of hypokalemia, myopathy/ rhabdomyolysis may occur. If weakness, As a result of hypokalemia, myopathy/ rhabdomyolysis may occur. If weakness, muscle weakness, myalgia, convulsion/paralysis of limbs, increased CK(CPK), incrmuscle weakness, myalgia, convulsion/paralysis of limbs, increased CK(CPK), increased blood/urinary myoglobin are observed, administration should be discontinueeased blood/urinary myoglobin are observed, administration should be discontinued and appropriate measures such as an administration of a potassium preparation td and appropriate measures such as an administration of a potassium preparation taken.aken.
The ADR which does the origin in the crude drugs 4The ADR which does the origin in the crude drugs 4
ItemItem DescriptionDescription CaseCase
PRECAUPRECAUTIONSTIONS
HypersensitivityHypersensitivity: Rash, redness, pruritus, etc. may occur.If : Rash, redness, pruritus, etc. may occur.If such symptoms are observed, administration should be discosuch symptoms are observed, administration should be discontinued.ntinued.
Mention it in all of Mention it in all of the cinnamon the cinnamon containing containing prescriptions.prescriptions.
ItemItem DescriptionDescription CaseCase
PRECAUPRECAUTIONSTIONS
HypersensitivityHypersensitivity: Rash, urticaria, etc. may occur. If such sy: Rash, urticaria, etc. may occur. If such symptoms are observed, administration should be discontinued.mptoms are observed, administration should be discontinued.
Mention it in all of Mention it in all of the Ginseng the Ginseng containing containing prescriptions.prescriptions.
ItemItem DescriptionDescription CaseCase
Use during Use during Pregnancy, Pregnancy, Delivery or Delivery or LactationLactation
Use of this product in pregnant women, women who may Use of this product in pregnant women, women who may possibly be pregnant is not recommended. [Moutan Bark possibly be pregnant is not recommended. [Moutan Bark contained in this product may cause premature contained in this product may cause premature birth or abirth or abortionbortion.].]
Mention it in all of tMention it in all of the Moutan containihe Moutan containing prescriptions.ng prescriptions.
JP Cinnamon Bark
JP Ginseng
JP Moutan Bark
Literature
Literature
Literature
Post-marketing surveillancePost-marketing surveillance (( PMSPMS )) systemssystems in in JapanJapan
Kampo Medicines
Adverse Drug Reaction and Infectious Disease Reporting System
Reexamination system Reevaluation
system
Periodic Safety Reports
6 years as a rule (4 ~ 10years)
EPPV
Initial 2 years : every 6 months
Thereafter : every year PMDA
MHLW
6 months after launch
report
report
every 5 years
report
EPPV :Early Post-Marketing Phase Vigilance
Thank you for your attentionThank you for your attention